We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
+19.36%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$2.05B
AUM Growth
+$259M
Cap. Flow
+$4.36M
Cap. Flow %
0.21%
Top 10 Hldgs %
24.09%
Holding
255
New
12
Increased
112
Reduced
101
Closed
15

Sector Composition

Rank Sector Weight
1 Healthcare 33.48%
2 Technology 28.09%
3 Industrials 14.98%
4 Consumer Discretionary 7.96%
5 Communication Services 5.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LGND icon
1
Ligand Pharmaceuticals
LGND
$5.69B
$85.4M 4.15%
270,052
-13,515
-5% -$3.18M
ACIW icon
2
ACI Worldwide
ACIW
$5.24B
$50.6M 2.46%
1,006,595
+3,239
+0.3% +$141K
ARLO icon
3
Arlo Technologies
ARLO
$1.42B
$50.3M 2.45%
3,732,962
+73,074
+2% +$990K
FN icon
4
Fabrinet
FN
$15B
$49.2M 2.4%
87,577
-18,238
-17% -$11.8M
ESTA icon
5
Establishment Labs
ESTA
$2.1B
$48.1M 2.34%
560,935
+12,261
+2% +$881K
XPO icon
6
XPO
XPO
$21.2B
$46.2M 2.25%
224,878
+579
+0.3% +$123K
ZD icon
7
Ziff Davis
ZD
$1.9B
$43M 2.09%
821,496
+21,678
+3% +$981K
FOUR icon
8
Shift4
FOUR
$3.58B
$42.5M 2.07%
874,492
+26,766
+3% +$1.16M
KNSA icon
9
Kiniksa Pharmaceuticals
KNSA
$6.01B
$40M 1.95%
624,928
+16,512
+3% +$857K
ASND icon
10
Ascendis Pharma A/S
ASND
$17.3B
$39.6M 1.93%
148,644
+258
+0.2% +$60.3K
LRN icon
11
Stride
LRN
$3.43B
$37.9M 1.84%
438,981
+541
+0.1% +$49.7K
PBH icon
12
Prestige Consumer Healthcare
PBH
$2.22B
$32.6M 1.59%
689,692
+168,070
+32% +$8.64M
DFIN icon
13
Donnelley Financial Solutions
DFIN
$1.18B
$32.5M 1.58%
775,119
-4,918
-0.6% -$214K
ITRN icon
14
Ituran Location and Control
ITRN
$1.04B
$29M 1.41%
475,496
-56,358
-11% -$3.35M
MEDP icon
15
Medpace
MEDP
$16.6B
$28.7M 1.39%
54,116
+133
+0.2% +$61.4K
AWI icon
16
Armstrong World Industries
AWI
$6.95B
$28.4M 1.38%
177,147
+290
+0.2% +$47.4K
GDDY icon
17
GoDaddy
GDDY
$12.3B
$28.1M 1.37%
330,474
+11,021
+3% +$930K
BIRK icon
18
Birkenstock
BIRK
$5.11B
$27.1M 1.32%
629,868
+39,500
+7% +$1.6M
YOU icon
19
Clear Secure
YOU
$4.39B
$27M 1.32%
485,011
-92,070
-16% -$5.03M
NGVT icon
20
Ingevity
NGVT
$2.36B
$26.2M 1.28%
351,203
+6,065
+2% +$437K
WEX icon
21
WEX
WEX
$6.54B
$25.2M 1.23%
178,606
-1,708
-0.9% -$253K
SRAD icon
22
Sportradar
SRAD
$3.84B
$23.9M 1.16%
1,597,682
+15,500
+1% +$225K
LQDT icon
23
Liquidity Services
LQDT
$1.33B
$23.8M 1.16%
608,476
+11,233
+2% +$398K
AGM icon
24
Federal Agricultural Mortgage
AGM
$2.47B
$23.5M 1.15%
118,094
+3,389
+3% +$594K
BCRX icon
25
BioCryst Pharmaceuticals
BCRX
$2.09B
$23.3M 1.14%
2,332,043
+101,938
+5% +$922K

Similar funds

Rice Hall James & Associates's Q2 2026 Portfolio in Review

As of Q2 2026, Rice Hall James & Associates held 255 positions worth $2.05B, up 14% from $1.8B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rice Hall James & Associates's Q2 2026 filing shows 12 new, 112 increased, 101 reduced and 15 closed positions. Its largest new stake was Oshkosh: 106,011 shares worth $16.3M. The largest sale was Aehr Test Systems, an estimated $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Industrials.

  • Rice Hall James & Associates's largest Q2 2026 buy was Oshkosh: 106,011 shares worth $16.3M.
  • Rice Hall James & Associates added most to Upwork in Q2 2026, an estimated $13.9M increase.
  • Rice Hall James & Associates's biggest Q2 2026 reduction was Aehr Test Systems, cutting an estimated $16.9M.
  • Rice Hall James & Associates fully exited Amicus Therapeutics in Q2 2026, selling an estimated $11.1M.
  • Rice Hall James & Associates's ten largest holdings make up 24% of its $2.05B portfolio in Q2 2026.
  • Rice Hall James & Associates opened 12 new positions and closed 15 in Q2 2026.
  • Rice Hall James & Associates's portfolio value rose 14% quarter-over-quarter to $2.05B.

Based on Rice Hall James & Associates's 13F filing for Q2 2026, filed 7 Aug 2026.